• Compass Pathways reported a published post-hoc analysis of an open-label Phase 2 PTSD study of COMP360 synthetic psilocybin.
• Analysis found 78% of dosing sessions were silent, with patient support described as minimal, non-directive monitoring rather than psychotherapy.
• Company framed the results as supporting attribution of rapid, durable symptom improvement to the drug experience, not “psilocybin-assisted psychotherapy.”

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260716248636) on July 16, 2026, and is solely responsible for the information contained therein.